Updates

Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 29 September 2026 National Stock Exchange of India Limited BSE Limited Scrip Name: SUNPHARMA Scrip Code: 524715 ESG Overview for FY 2025-26 We are submitting herewith the ESG Overview of the Company for the financial year 2025-26, which shall be released after this submission. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary & Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA. Reaching People. Touching Lives. Cover Contents 01 56 87 About the Report Ethical Clinical Trials Climate Governance 02 58 92 About Sun Pharma Ethical Marketing Biodiversity Management 03 95 ESG Highlights Environmental Product Enhancing Access to Healthcare Stewardship Corporate Governance & Ethics Information Security Management Workforce Resilience and & Responsible AI usage Wellbeing Business Ethics Responsible Environmental Human Rights 14 Initiatives Tax Strategy and Reporting 75 110 Ensuring Employee Well-being, 23 Efficient Energy Management Health, and Safety Risk Management 79 37 GHG Emissions Performance Sustainable Supply Chain Management Stakeholder Engagement and Materiality Assessment 82 GRI Index 46 Waste and Pollutants Product Quality and Safety Assurance Statement Water Management About the Report Sun Pharmaceutical Industries Limited, (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma”, along with its subsidiaries and/or associate companies), headquartered in Mumbai, India presents the ESG Overview for the fiscal year 2025-26. This ESG Overview outlines our company’s ESG performance from April 01, 2025 to March 31, 2026. Reporting Frameworks and Scope and Reporting Benchmarks Boundary This Report has been developed with reference to the The reporting boundary comprises 44 manufacturing Global Reporting Initiative (GRI) Standards 2021. We locations and R&D centres across Sun Pharma’s national participate in global ESG rating assessments, including the and international operations, covering 84% of operational S&P Global Corporate Sustainability Assessment (CSA), sites for EHS-related indicators (~97% of our revenues), EcoVadis and CDP’s Climate Change and Water disclosures since the remaining sites account for only ~3% of total (erstwhile Carbon Disclosure Project). This Report details revenue, they are not considered significant contributors the assumptions and methodologies behind our estimates. based on the materiality considerations. 100% of The GRI Index is appended to this report. operational sites for all other indicators (~100% of our revenues) have been considered. External Assurance The information presented in the report has been externally assured by DNV Business Assurance India Private Limited. Feedback It is our endeavor to seek feedback on our sustainability performance disclosures from all our stakeholders. Please share your feedback, suggestions and/or queries at: secretarial@sunpharma.com ESG Overview FY2025-26 01 About Sun Pharma Recognized and trusted by healthcare professionals and Pharmaceutical Ingredients (APIs), and intermediates— patients alike, Sun Pharma stands as a leading global underscoring our commitment to accessible and innovative player in the specialty generic pharmaceutical industry, healthcare solutions. Our business operations and long- with revenues of USD 6.6 billion. We provide high-quality term value creation are anchored in our vision: “Reaching medicines across approximately 100 countries, supported people and touching lives globally as a leading provider of by 40 state-of-the-art manufacturing facilities and strong valued medicines.” This vision is brought to life through our R&D capabilities. Our diverse product portfolio includes deeply held core values. At Sun Pharma, we foster a culture generics, branded generics, specialty medicines, complex that creates meaningful impact, built on four foundational formulations, technology-driven therapies, over-the- pillars—Humility, Integrity, Passion, and Innovation. counter (OTC) products, antiretrovirals (ARVs), Active At Sun Pharma, our commitment to long-term growth and value creation for all stakeholders. Our growth strategy is centered around four key pillars: Sustainable Enhancing business Cost Balancing Profitability growth development leadership and Investments for the Future Since inception to realize this strategy and ensure consistent business success, we have made focused investments in four core capabilities: Research & Our Our Our Development and Workforce Portfolio Geographical Reach Manufacturing Geographical Reach 55,000+ 40 100 Mumbai Total workforce worldwide manufacturing facilities Markets presence- - Headquarters and 4 R&D centers Approximately across five continents Read more about SUN PHARMACEUTICAL INDUSTRIES LIMITED on: Sun Pharma Annual Report FY 2026 on page 4 of 344 02 ESG Overview FY2025-26 ESG Performance Highlights Environment Social Governance 15.86% Reduction in absolute 17.97% female representation 95.24% Average Board carbon emissions and 48.64% across our global workforce. meeting attendance. decrease in specific intensity for Scope 1 and 2 carbon emissions 13.44% Women in top 50% Independent Board compared to baseline year 2020. Management Positions. Directors. 16.05% Reduction in absolute 26.39% Women in revenue water consumption and 48.72% generating functions. decrease in specific intensity for water consumption compared to baseline year 2020. 25.29% Women in STEM related positions. 43% Energy sourced from renewable sources. INR 2,068 million CSR spend. Nearly 2.23 million lives touched in India through CSR initiatives. ESG Overview FY2025-26 03 Corporate Governance & Ethics At Sun Pharma, we are committed to high standards of stakeholder and adheres to regulatory requirements. We business integrity through robust governance structures have adopted a top-down approach to boost operational and processes. Our corporate governance philosophy excellence, supported by a diverse, industry-experienced is grounded in principles of trust, accountability, one-tier Board of Directors. Our diverse, single-tier Board reliability and transparency, reflecting our commitment of Directors represents this approach, comprising highly to excellence in all our operations. In our commitment motivated and dedicated industry experts. The Board to creating a sustainable business, we prioritize our and its committees strictly oversee the implementation core values and strive to create an environment of trust of the Global Code of Conduct (GCoC), company policies, through transparent and accountable communication processes, and compliance with local laws and regulations. with stakeholders, whilst promoting responsible and This approach highlights our dedication to responsible sustainable decision-making. Our robust corporate business practices throughout our operations and value governance framework enhances transparency for all chain. Charting a Legacy of Ethical Leadership Board of Directors Mr. Dilip Shanghvi1 Mr. Kirti Ganorkar2 Dr. Pawan Goenka Mr. Aalok D. Shanghvi Executive Chairman Managing Director Lead Independent Director Whole-time Director and NRC CSR RMC SRC CGESGC A NRC SRC CSR RMC Chief Operating Officer CGESGC SRC RMC Ms. Satyavati Berera3 Ms. Vidhi D. Shanghvi4 Mr. Gautam Doshi Mr. Rolf Hoffmann Independent Director Whole-time Director and Independent Director Independent Director Head – CHC A NRC SRC RMC CGESGC NRC 1 Stepped down as Managing Director effective from September 01, 2025 and continues to be the Executive Chairman. 2Appointed as Managing Director effective from September 01, 2025. 3 Appointed as a Non-Executive Independent [Showing first 8,000 characters — download PDF for full document]